URGN’s Urogen gains options for exclusive worldwide Oncology license
URGN’s intragel Therapeutics unit, Urogen, gains options for an exclusive worldwide license to develop up to three Oncology products, according to Hammerstone MarketTalk.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.